PMID- 32368936
OWN - NLM
STAT- MEDLINE
DCOM- 20220207
LR  - 20220207
IS  - 2327-9109 (Electronic)
IS  - 2327-9095 (Linking)
VI  - 29
IP  - 2
DP  - 2022 Mar-Apr
TI  - RehaCom rehabilitation training improves a wide-range of cognitive functions in 
      multiple sclerosis patients.
PG  - 262-272
LID - 10.1080/23279095.2020.1747070 [doi]
AB  - Multiple sclerosis (MS) is a chronic neurodegenerative disease that impairs 
      cognitive performance. Attention, response control, working memory, and 
      processing speed are highly impaired in MS. On the other hand, RehaCom is a 
      computerized software that improves cognitive dysfunctions. In this study, we 
      aimed to investigate the effect of RehaCom on attention, response control, 
      processing speed, working memory, visuospatial skills, and verbal/non-verbal 
      executive functions in MS patients. Sixty patients were selected randomly and 
      divided into control (n = 30) and experimental (n = 30) groups. Integrated 
      Auditory Visual-2 (IVA-2), Paced Auditory Serial Addition Test (PASAT), Symbol 
      Digit Modalities Test (SDMT), Judgment of Line Orientation (JLO) and The 
      Delis-Kaplan Executive Function System (DKEFS) were used to assess cognitive 
      functions. Patients in the experimental group were treated by RehaCom for 5 weeks 
      (two 60-min sessions per week). Cognitive performance of all patients in both 
      groups was assessed at weeks 5 and 10 (post-test and follow-up stages, 
      respectively). The results showed that RehaCom treatment improved all studied 
      cognitive functions at the post-test stage. This effect also remained at the 
      follow-up stage for some cognitive functions. In conclusion, treatment with 
      RehaCom may have significant therapeutic effects on cognitive dysfunctions in MS 
      patients.
FAU - Naeeni Davarani, Mahsa
AU  - Naeeni Davarani M
AD  - Department of Psychology, Faculty of Medicine, Tehran Medical Sciences, Islamic 
      Azad University, Tehran, Iran.
FAU - Arian Darestani, Ali
AU  - Arian Darestani A
AD  - Department of Psychology, Faculty of Medicine, Tehran Medical Sciences, Islamic 
      Azad University, Tehran, Iran.
FAU - Hassani-Abharian, Peyman
AU  - Hassani-Abharian P
AD  - Department of Rehabilitation, Brain and Cognition Clinic, Tehran, Iran.
AD  - Institute for Cognitive Science Studies (ICSS), Tehran, Iran.
FAU - Vaseghi, Salar
AU  - Vaseghi S
AD  - Institute for Cognitive Science Studies (ICSS), Tehran, Iran.
AD  - Cognitive and Neuroscience Research Center (CNRC), Amir-Almomenin Hospital, 
      Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
FAU - Zarrindast, Mohammad-Reza
AU  - Zarrindast MR
AD  - Institute for Cognitive Science Studies (ICSS), Tehran, Iran.
AD  - Department of Pharmacology School of Medicine, Tehran University of Medical 
      Sciences, Tehran, Iran.
AD  - Department of Neuroendocrinology, Endocrinology and Metabolism Research 
      Institute, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Nasehi, Mohammad
AU  - Nasehi M
AD  - Cognitive and Neuroscience Research Center (CNRC), Amir-Almomenin Hospital, 
      Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20200505
PL  - United States
TA  - Appl Neuropsychol Adult
JT  - Applied neuropsychology. Adult
JID - 101584082
SB  - IM
MH  - Cognition
MH  - Executive Function
MH  - Humans
MH  - *Multiple Sclerosis/complications
MH  - *Neurodegenerative Diseases
MH  - Neuropsychological Tests
OTO - NOTNLM
OT  - Attention
OT  - RehaCom
OT  - executive functions
OT  - multiple sclerosis (MS)
OT  - working memory
EDAT- 2020/05/06 06:00
MHDA- 2022/02/08 06:00
CRDT- 2020/05/06 06:00
PHST- 2020/05/06 06:00 [pubmed]
PHST- 2022/02/08 06:00 [medline]
PHST- 2020/05/06 06:00 [entrez]
AID - 10.1080/23279095.2020.1747070 [doi]
PST - ppublish
SO  - Appl Neuropsychol Adult. 2022 Mar-Apr;29(2):262-272. doi: 
      10.1080/23279095.2020.1747070. Epub 2020 May 5.